About Ibritumomab
Class: | Radiopharmaceutical, Monoclonal Antibody
Use: | Ibritumomab (ZEVALIN KIT) is used for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Adult dose: | The standard adult dosing involves a two-step regimen: first, an infusion of rituximab followed by a dose of indium-111-labeled ibritumomab tiuxetan for imaging, and then a second infusion of rit
Drug Class
Radiopharmaceutical, Monoclonal Antibody
Uses & Indications
Ibritumomab (ZEVALIN KIT) is used for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Storage Requirements
Store the kit at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
Manufacturer & Packaging
Manufacturer: Bayer AG, GERMANY
Package Size
2ml Vial
Price & Supplier
Price in UAE: AED 70772.70
Dosage Information
Adult Dose
The standard adult dosing involves a two-step regimen: first, an infusion of rituximab followed by a dose of indium-111-labeled ibritumomab tiuxetan for imaging, and then a second infusion of rituximab followed by a dose of yttrium-90-labeled ibritumomab tiuxetan. The therapeutic dose of yttrium-90 ibritumomab tiuxetan is calculated based on body weight and platelet count.
Pediatric Dose
Not applicable; safety and efficacy have not been established in pediatric patients.
Side Effects
Common side effects include thrombocytopenia, neutropenia, anemia, nausea, infections, fever, fatigue, cough, and diarrhea.
Contraindications & Precautions
Contraindicated in patients with known hypersensitivity to murine proteins or any component of the formulation, and in patients with ≥25% lymphoma marrow involvement or impaired bone marrow reserve.
Important Warnings
Important safety warnings include the risk of severe and prolonged cytopenias, serious infections, and infusion-related reactions. It is essential to monitor blood counts regularly and manage any adverse reactions promptly. Use of this drug requires specialized training and should be administered under the supervision of a qualified healthcare professional experienced in the use of radiopharmaceuticals.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.